The regents convened at 3:00 p.m. in the Anderson Room, Michigan Union. Present were President Coleman and Regents Bernstein, Darlow, Deitch, Diggs, Ilitch, Newman, Richner, and White. Also present were Vice President and Secretary Churchill, Vice President Forrest, Provost Hanlon, Vice President Harper, Chancellor Little, Vice President Lynch, Vice President May, Chancellor Person, Executive Vice President Pescovitz, Vice President Rudgers, Executive Vice President Slottow, and Vice President Wilbanks.

Call to Order and President’s Opening Remarks

President Coleman welcomed Regents Bernstein and Diggs to their first meeting, noting that the two of them collectively hold five UM degrees, including a juris doctorate and a medical degree. She also noted that the agenda includes a request for approval of Martha Pollack as the University’s next provost and executive vice president for academic affairs.

President Coleman then commented on Professor Yukiko Yamashita of the Life Sciences Institute and the Department of Cell and Developmental Biology, who was awarded a $500,000 grant from the W.M. Keck Foundation for her work in studying how stem cells divide. She commended Professor of Mathematics, Steven DeBacker, a Thurnau professor who was named the 2012 Professor of the Year by the Carnegie Foundation for the Advancement of Teaching and the Council for Advancement and Support of Education. Provost Hanlon added that Professor DeBacker’s encouragement and support of students and mathematics has made him a teacher who is considered by students to be both difficult and great.
Regent Deitch officially presented Professor DeBacker with the award, and thanked him for his outstanding contribution to the University.

Regent Deitch, continued, with an update on the Regents’ meetings in California in January to meet with donors, and university leaders. He said that the trip was a first, and benefitted the university in several ways, including providing an opportunity to get to know the two new regents, meeting distinguished university leaders from UC Berkley, and Stanford, and connecting with an important donor constituency. Southern California is an important area in terms of donors and private support, and donors acknowledged their appreciation of the Regents’ outreach.

President Coleman noted that the University of Michigan continues to be the number one public university for research spending; yet federal spending cuts loom large in these precarious times. It is in this context that she invited Stephen Forrest, vice president for research, to present his annual report.

**Presentation: “Annual Research Report”**

Vice President Forrest commented on steps being taken in anticipation of federal budget cuts. He noted the strengths of UM research, including its size, breadth, excellence, and interdisciplinary systems focus. The University’s ability to capitalize on a culture of cooperation with industry, build on the inherent strengths, and utilize the facilities at the North Campus Research Complex will be key to the institution’s continued growth and success.

**Public Comment on Agenda-Related Items**

Linda Martinson commented on the Litigation Report. President Coleman then turned to the regular agenda.
Committee Reports

Finance, Audit and Investment Committee. Regent White, chair of the Finance, Audit and Investment Committee, reported that the committee, consisting of herself, and Regents Richner and Bernstein had met with Executive Vice President Slottow. They were joined by the Health Affairs Committee members, Regents Darlow, Deitch and Diggs, and received an update on the UMHS 10 Year Strategic Financial Plan, with Executive Vice President Pescovitz, UMHHS CEO Doug Strong, Medical School Dean Woolliscroft and Health System CFO Paul Castillo. The committee met privately with the Jeff Moelich, executive director of internal audits, for an update on university audits. The committee then met with President Coleman and the Personnel, Compensation and Governance Committee, for an overview of the FY2014 General Fund. They were joined by Provost Hanlon, Vice Provost Martha Pollack, Vice President for Government Relations, Cynthia Wilbanks, General Counsel, Tim Lynch, and Chancellors Little and Person.

Health Affairs Committee. Regent Darlow, chair of the Health Affairs Committee, reported that she and Regents Deitch and Diggs met with the Finance, Audit and Investment Committee for the UMHS 10 Year Strategic Financial Plan update. The committee then received an update on the Health System finances from Executive Vice President Pescovitz, Dean Woolliscroft, UMHHC CEO Doug Strong, Health System CFO Paul Castillo, and UMHHC COO Tony Denton.

Personnel, Compensation and Governance Committee. Regent Ilitch, chair of the Personnel, Compensation and Governance Committee, met with Regents Newman and Diggs, along with President Coleman and Provost Hanlon, and Vice Provost Martha Pollack. They received an update from the provost on current dean searches, and then met with Chancellors
Little and Person for an update on their campuses. General Counsel Tim Lynch and Laurita Thomas, associate vice president for human resources, provided an updated policy on background checks at the University. The committee then joined the FAI Committee and received an overview of the FY2014 General Fund Budget.

President Coleman welcomed new Vice President and General Counsel Timothy Lynch to his first Regents’ meeting.

Consent Agenda

Minutes. Vice President Churchill submitted for approval the minutes of the meeting of December 13, 2012.

Reports. Executive Vice President Slottow submitted the Investment Report, the Plant Extension Report, and the Regents’ Report on Non-Competitive Purchases over $5,000 from Single Sources, September 16, 2012 through December 15, 2012. There was no University Human Resources Report.


University of Michigan Health System. Executive Vice President Pescovitz had no additional report.

Division of Student Affairs. Vice President Harper commented on the South Quadrangle schematic design, presented later in the meeting, as well as the recommendation of West Quadrangle and Cambridge House renovations. All of these projects will continue to improve the residential experience for students.
University of Michigan-Dearborn. Chancellor Little reported on the Dearborn Campus, and his testimony to the Michigan House Appropriations Subcommittee on Higher Education on how UM-Dearborn is taking steps to keep higher education affordable, accessible and excellent. He also reported on the official name change from Wolves to Wolverines for all athletic programs on the UM-Dearborn Campus.

University of Michigan-Flint. Chancellor Person reported that the *US News and World Report* named UM-Flint the third best on-line graduate program in nursing, and the *Huffington Post* named the UM-Flint the third best satellite campus in the United States.

Central Student Government Report. Manish Parikh gave a summary of recent projects and activities of the Central Student Government, including efforts to enhance entrepreneurship, study abroad and student elections.


Personnel Actions/Personnel Reports. Provost Hanlon submitted a number of personnel actions and personnel reports. He commented on the recommended appointments of Mark D. West, dean of the Law School, and Terrance McDonald, director of the Bentley Library, and the recommendations for six faculty members to be named Thurnau professors, the highest honor that the University can bestow upon members of the faculty to recognize excellence in undergraduate teaching.

Retirement Memoirs. Vice President Churchill submitted 11 faculty retirement memoirs.

Memorials. Vice President Churchill submitted memorials for two faculty members: W. Shaun Jackson, B.S., professor of art and design, professor of architecture, and professor of
operations and management science, who died on January 15, 2013, and Hanes Walton, Jr., Ph.D., professor of political science, secretary to the faculty, and research professor, who died on January 8, 2013.

Degrees. Provost Hanlon submitted final degree lists for December 2012 and changes to previously approved degree lists.

Approval of Consent Agenda. On a motion by Regent White, seconded by Regent Richner, the regents unanimously approved the consent agenda.

Internal Audit Report

Executive Vice President Slottow presented the report of University Internal Audits, from the period October – November 2012.

Supplemental Information for the Audited Financial Statement

Executive Vice President Slottow presented supplemental information for the Audited Financial Statement for the Department of Intercollegiate Athletics for the year ended June 30, 2012.

Alternative Asset Commitments

Executive Vice President Slottow reported on the University’s follow-on investments with the previously approved investment managers: real estate partnership with Crow Holdings Realty Partners VI, L.P., private equity partnership with Silver Lake Partners IV, L.P., and venture capital partnerships with Sequoia Capital U.S. Venture Fund XIV, L.P. and Sequoia Capital China Venture Fund IV, L.P.
Approval of the Highclere International Investors and Polunin Capital Partners Ltd.

On a motion by Regent White, seconded by Regent Newman, the Regents approved a commitment of $75 million from the Long Term Portfolio to Highclere International Investors, and a commitment of $50 million from the Long Term Portfolio to Polunin Capital Partners Ltd.

Varsity Drive Building

On a motion by Regent White, seconded by Regent Ilitch, the regents unanimously approved the Varsity Drive Building Dry Collections Relocation Renovations project as described and authorized commissioning SmithGroupJJR for its design.

College of Pharmacy Building

A presentation for the College of Pharmacy project was given by Director of Design, James Lucky, of the SHW Group, which included renovation of approximately 12,000 square feet.

On a motion by Regent White, seconded by Regent Newman, the regents unanimously approved the College of Pharmacy Building Basement and First Floor Renovations, and authorized issuing the project for bids and awarding construction contracts providing that bids are within the approved budget.

South Quadrangle Renovation

Christopher Purdy, vice president, SmithGroupJJR gave a presentation of the South Quadrangle renovation, which included a consolidated dining facility on Central Campus serving South Quadrangle, West Quadrangle and Helen Newberry Hall.

On a motion by Regent Richner, seconded by Regent Deitch, the regents unanimously approved the South Quadrangle Renovation Schematic Design, as presented.
West Quadrangle and Michigan Union-Cambridge House Renovation

On a motion by Regent Bernstein, seconded by Regent White, the regents unanimously approved the West Quadrangle and Michigan Union-Cambridge House Renovation Project and authorized commission Integrated Design Solutions LLC for its design.

Conflict of Interest Items

President Coleman said the agenda includes 13 conflict of interest items, each of which requires six votes for approval, and which would be approved by a single motion.

On a motion by Regent White, seconded by Regent Darlow, the regents unanimously approved the following 13 items:

Authorization for the University of Michigan to Enter into Lease Agreements with Venture Accelerator Firms located at the North Campus Research Complex

The regents approved lease agreements for space in the North Campus Research Complex start-up accelerator, located at 1600 Huron Parkway, Ann Arbor, with both companies listed in the spreadsheet that is part of the Regents Communication. The space will be utilized as office and lab space for research and business operations for each respective company. The companies have separately entered into a relationship agreement defining the relationship between the University of Michigan and them at the accelerator. Because those named for each respective company included in the Regents Communication (and listed below) are University of Michigan employees, and are party to the lease by virtue of their share of the ownership of each respective company, membership on respective tenant board of directors, or acting as an officer in the tenant company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:
1. Parties to the agreement are the Regents of the University of Michigan and the companies listed in spreadsheet that is part of the Regents Communication, and listed here: 1) Exo Dynamics LLC, and 2) OncoFusion Therapeutics.

2. The service to be provided is the lease of space in the North Campus Research Complex start-up accelerator, located at 1600 Huron Parkway, Ann Arbor, Michigan with access to common area space within the building. The lease durations including all options for renewal are outlined in the spreadsheet. The leases will use the standard University of Michigan accelerator lease template. Tenant will pay rates stipulated in the spreadsheet for the current term and option years as indicated with a monthly rate as follows: 1) $2,500, and 2) $250. All companies will be responsible for providing monthly updates concerning their business progress to the University of Michigan Office of Technology Transfer, and will have access to Office of Technology Transfer personnel for advice concerning obtaining technology assessment, business consulting, technical assistance, capital raising, or other business services.

3. The pecuniary interest arises from the fact that the individuals listed on the spreadsheet (and listed below) for each company are University of Michigan employees, and also owners and/or officers of each respective company: 1) Jorg Sanz-Guerrero and Dan Johnson, and 2) Shaomeng Wang and Arul Chinnaiyan.

Authorization for the University of Michigan to Transact with Avicenna Medical Systems, Inc.

The regents unanimously approved a Sub-Lease agreement with Avicenna Medical Systems, Inc. (the “Company”) for programming services.

Because Frank Pelosi, M.D., Erdwing Coronado and Khaled El-Safty, University of Michigan employees, are also partial owners of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and its Health System (UMHS) and Avicenna Medical Systems, Inc.

2. The agreement is for services required to modify and test existing patient tracking software. The total cost is $6,900.

3. The pecuniary interest arises from the fact that University of Michigan employees Frank Pelosi, M.D., Erdwing Coronado and Khaled El-Safty are also owners of Avicenna Medical Systems, Inc.
Authorization for the University to Purchase from A2 Laboratory

The regents unanimously approved a contract with A2 Laboratory, (the “Company”) to purchase in a two-step process. The first step would be to issue a no-charge purchase order to secure five prototype dental appliances for evaluation by the School of Dentistry. If after a trial period the prototypes compete in quality with current aligners, the second step would involve purchasing a two-year supply of appliances.

Because Airton Arruda, a University of Michigan employee, is also founder of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan, its School of Dentistry, and A2 Laboratory.
2. The agreement is to issue a no-charge purchase order with A2 Laboratory to secure five (5) sample dental appliances for evaluation by the School of Dentistry. If after a trial period the prototypes compete in quality with the current aligners, the second step would involve purchasing a two-year supply of the appliances for a total of $20,000.
3. The pecuniary interest arises from the fact that University of Michigan employee Airton Arruda is founder and CEO of A2 Laboratory.

Authorization for the University to contract with Talley Photo+graphics

The Regents unanimously approved an agreement with Talley Photo+graphics (the “Company”) for software and services required to update the Department of Nursing website with the new Nursing Governance Structure.

Because Kathleen Talley, a University of Michigan employee, is also owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan, its Department of Nursing and Talley Photo+graphics.
2. The agreement is for software and services required to update the Department of Nursing website with the new Nursing Governance Structure. The cost for said work will be $549.

3. The pecuniary interest arises from the fact that University of Michigan employee, Kathleen Talley, is the owner of Talley Photo+graphics.

Amendment to License Agreement between the University of Michigan and Ascentage Pharma Group Corporation, Ltd.

The Regents unanimously approved an agreement with Ascentage Pharma Group Corporation, Ltd. (the “Company”) to add to its existing license with the University’s rights associated with the following technologies: UM OTT File No. 4028, entitled: “SMAC Mimetics;” UM OTT File No. 2784, entitled: “Apogossypolone and the Method of Use of the Treatment of Human Cancer and Other Conditions;” and UM OTT File No. 5229, entitled: “Cyclized Pepitdomimetic Small Molecule Inhibitors of the WDR5 and MLL1 Interaction.”

Because Professor Shaomeng Wang, University of Michigan employee, is also partial owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and Ascentage Pharma Group Corporation, Ltd.

2. Agreement terms include granting the Company an exclusive license with the right to grant sublicenses. The Company will pay a license fee, annual minimums, milestone payments, royalties on sales and reimburse patent costs. The University will retain ownership of the licensed technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Pursuant to the Michigan Investment in New Technology Startups program (“MINTS”) approved by the Regents on December 15, 2011, the University may invest up to $1,000,000 per qualifying financing round up to, for purposes of this approval, a total of $2.5 million in this Company.

3. The pecuniary interests of Dr. Wang arise from his ownership interest in Ascentage Pharma Group Corporation, Ltd.
Amendment to License Agreement between the University of Michigan and Ambiq Micro, Inc.

The Regents unanimously approved an agreement with Ambiq Micro, Inc. (the “Company”) to add to its existing license with the University’s rights associated with the following technologies: UM OTT File No. 5252, entitled: “Pulse Injection Crystal Oscillator.”

Because Professors Dennis Sylvester and David Blaauw, University of Michigan employees, are also partial owners of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and Ambiq Micro, Inc.
2. Agreement terms include granting the Company an exclusive license with the right to grant sublicenses. The Company will pay royalties on sales and reimburse patent costs. The University will retain ownership of the licensed technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interests of Drs. Sylvester and Blaauw arise from their ownership interest in Ambiq Micro, Inc.

Research Agreement between the University of Michigan and Armune BioScience, Inc.

The Regents unanimously approved an agreement with Armune BioScience, Inc. (the “Company”) to support a research project directed by Dr. Xiaoju Wang in the University’s Department of Pathology entitled “Prostate Cancer Biomarker Transfer” (UM ID 13-PAF03131), which requires the use of facilities and resources of the University.

Because Professors Beer, Chinnaiyan and Omenn, University of Michigan employees, are also partial owner of the Company, this agreement falls under the State of Michigan Conflict
of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and Armune BioScience, Inc.
2. The terms of the agreement conform to University policy. The period of performance for the project is expected to be five (5) months and the amount of funding support is anticipated at $20,771.
3. The pecuniary interests of Drs. Beer, Chinnaiyan and Omenn arise from their ownership interest in Armune BioScience, Inc.

**Option Agreement between the University of Michigan and Biocrede, Inc.**

The Regents unanimously approved an agreement with Biocrede, Inc. (the “Company”) to obtain an option from the University of Michigan for the University’s rights associated with the following technologies: UM OTT File No. 5584, entitled: “Polyurethanes for Nitric Oxide Release.”

Because Dr. Hao Chen, University of Michigan employee, is also partial owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and Biocrede, Inc.
2. Agreement terms include granting the Company an exclusive option. The Company will pay an option fee and reimburse patent costs. The University will retain ownership of the optioned technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interests of Dr. Chen arise from his ownership interest in Biocrede, Inc.

**Option Agreement between the University of Michigan and Cardiavent, Inc.**

The Regents unanimously approved an agreement with Cardiavent, Inc. (the “Company”) to add to its existing option agreement with the University’s rights associated with the following
technology: UM OTT File No. 5383, entitled: “CARD-024 Amelioration of Intestinal Fibrosis and use for Treatment of Crohn’s Disease.”

Because Professor Robert Simpson, University of Michigan employee, is also partial owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and Cardiavent, Inc.

2. Agreement terms include granting the Company an exclusive option to the above technology. The Company will pay an option fee and reimburse patent costs incurred during the term of the option agreement. The University will retain ownership of the optioned technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interests of Dr. Simpson arise from his ownership interest in Cardiavent, Inc.

Option Agreement between the University of Michigan and Ektapharm, Inc.

The Regents unanimously approved an agreement with Ektapharm, Inc. (the “Company”) to obtain option agreement with the University’s rights associated with the following technologies: UM OTT File No. 2151.1, entitled: “Methods for Stabilizing Biologically Active Agents Encapsulated in Biodegradable Controlled-Release Polymers;” UM OTT File No. 2865, entitled: “Effects on the Controlled Release of Proteins;” and UM OTT File No. 4518, entitled: “Active Self-Healing Biomaterial System With High Encapsulation Efficiency for Biomacromolecule Delivery.”

Because Professor Steven Schwendeman, University of Michigan employee, is also partial owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:
1. Parties to the agreement are the Regents of the University of Michigan and Ektapharm, Inc.

2. Agreement terms include granting the Company an exclusive option to obtain an exclusive license with the right to grant sublicenses. The Company will pay an option fee and reimburse ongoing patent expenses. The terms of the subsequent license agreement would include payment of royalty on sales and reimbursement of patent costs. The University may receive equity in the Company, along with the right to purchase more equity. The University will retain ownership of the optioned technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interests of Dr. Schwendeman arise from his ownership interest in Ektapharm, Inc.

License Agreement between the University of Michigan and H3D, Inc.


Because Professor Zhong He and Dr. Feng Zhang, University of Michigan employees, are also partial owners of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and H3D, Inc.

2. Agreement terms include granting the Company an exclusive license with the right to grant sublicenses. The Company will pay royalties on sales and reimburse patent costs. The University will retain ownership of the licensed technology and may
continue to further develop it and use it internally as well as in collaboration with other research institutions. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interests of Drs. He and Zhang arise from their ownership interest in H3D, Inc.

**Option Agreement between the University of Michigan and HiperNap, LLC**

The Regents unanimously approved an agreement with HiperNap, LLC. (the “Company”) to obtain option agreement with the University’s rights associated with the following technology: UM OTT File No. 5106, entitled: “High Performance Electromagnetic Actuators.”

Because Professor Shorya Awtar, University of Michigan employee, is also partial owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and HiperNap, LLC.

2. Agreement terms include granting the Company an option to further evaluate the subject technology and, upon meeting specific milestones, the ability to negotiate an exclusive license with the right to grant sublicenses. The Company will pay an option fee and reimburse patent costs. The University will retain ownership of the optioned technology and may continue to further develop it and use it internally as well as in collaboration with other research institutions. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interests of Dr. Awtar arise from his ownership interest in HiperNap, LLC.

**License Agreement between the University of Michigan and Optimal Process Technologies LLC**

The Regents unanimously approved an agreement with Optimal Process Technologies LLC (the “Company”) to obtain a license agreement with the University’s rights associated with the

Because Drs. Shixin Jack Hu and Tae Hyung Kim, University of Michigan employees, are also partial owners of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:

1. Parties to the agreement are the Regents of the University of Michigan and Optimal Process Technologies LLC.

2. Agreement terms include granting the Company an exclusive license with the right to grant sublicenses. The Company will pay royalties on sales and reimburse patent costs. The University will retain ownership of the licensed technology and may continue to further develop it and use it internally as well as in collaborations with other research institutions. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Pursuant to the Michigan Investment in New Technology Startups program (“MINTS”) approved by the Regents on December 15, 2011, the University may invest up to $1,000,000 per qualifying financing round up to, for purposes of this approval, a total of $2.5 million in this Company.

3. The pecuniary interests of Drs. Hu and Kim from their ownership interest in Optimal Process Technologies LLC.

Option Agreement between the University of Michigan and ResolveAble, Inc.

The Regents unanimously approved an agreement with ResolveAble Inc., (the “Company”) to obtain option agreement with the University’s rights associated with the following technology: UM OTT File No. 5327, entitled: “A System and Method for Resolving Arrest Warrants.”

Because Professor James Prescott, University of Michigan employee, is also partial owner of the Company, this agreement falls under the State of Michigan Conflict of Interest Statute. The following information is provided in compliance with statutory requirements:
1. Parties to the agreement are the Regents of the University of Michigan and ResolveAble, Inc.

2. Agreement terms include granting the Company an exclusive option, with the right to grant a single, time-limited, sublicense. The Company will pay an option fee and reimburse patent costs. The University will retain ownership of the optioned technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interests of Dr. Prescott arise from his ownership interest in ResolveAble, Inc.

**Public Comments**

Regents heard comments from the following individuals on the topics listed: Victoria Powell, citizen, on the Jenson/child pornography follow-up investigation; Brian Stone, student, on University acceptance of veterans as residents; Douglas Smith, citizen, on Black athletes; Peter Wasky, student, on renovations to student life facilities; Bonnie Halloran, faculty, status of current contract negotiations; Ian Matchett, student, on tuition and accessibility of education; Javier Contreras, citizen, on tuition equality for undocumented students; Arlette Cerdes, citizen, on tuition equality for undocumented students; Micah Nelson, student, on tuition equality; and Henry Greenspan, faculty, on LEO pay equity.

**Adjournment**

There being no further business, the meeting was adjourned at 5:10 p.m. The next meeting of the Board of Regents will take place on March 21, 2013.